share_log

Chimerix | 8-K: Current report

Chimerix | 8-K: Current report

Chimerix | 8-K：重大事件
美股SEC公告 ·  2024/07/04 03:16

Moomoo AI 已提取核心信息

On June 27, 2024, Chimerix received a notice from Nasdaq indicating non-compliance with Listing Rule 5450(a)(1), as its common stock price remained below $1.00 for 30 consecutive business days. The notification has no immediate impact on the company's listing status on The Nasdaq Global Market.The company has been granted a grace period until December 24, 2024, to regain compliance by maintaining a minimum bid price of $1.00 per share for at least ten consecutive business days. If unsuccessful, Chimerix may qualify for an additional 180-day compliance period by transferring to The Nasdaq Capital Market, provided it meets other listing requirements.Chimerix will actively monitor its stock price and explore options to regain compliance. Failure to meet the requirements could result in delisting from Nasdaq, though there is no guarantee the company will successfully regain compliance with the listing standards.
On June 27, 2024, Chimerix received a notice from Nasdaq indicating non-compliance with Listing Rule 5450(a)(1), as its common stock price remained below $1.00 for 30 consecutive business days. The notification has no immediate impact on the company's listing status on The Nasdaq Global Market.The company has been granted a grace period until December 24, 2024, to regain compliance by maintaining a minimum bid price of $1.00 per share for at least ten consecutive business days. If unsuccessful, Chimerix may qualify for an additional 180-day compliance period by transferring to The Nasdaq Capital Market, provided it meets other listing requirements.Chimerix will actively monitor its stock price and explore options to regain compliance. Failure to meet the requirements could result in delisting from Nasdaq, though there is no guarantee the company will successfully regain compliance with the listing standards.
2024年6月27日，Chimerix收到了纳斯达克的通知，指出未符合每股最低买盘价格1.00美元的要求，超过30个连续的业务日。公司必须在2024年12月24日前，通过保持至少10个连续业务日的最低买盘价格1.00美元，以重新获得合规。如果Chimerix未能满足这一要求，且符合其他上市标准，则可能有资格获得额外的180天合规期，条件是转到纳斯达克资本市场。公司计划积极监测其股票价格，并考虑期权以重新获得合规。未能重新获得合规可能导致从纳斯达克退市。通知不会立即影响Chimerix在纳斯达克全球市场的上市或交易。公司将探索可用的其他选项来应对这一情况，但并不能保证重新获得合规或维持其他纳斯达克上市标准的成功。
2024年6月27日，Chimerix收到了纳斯达克的通知，指出未符合每股最低买盘价格1.00美元的要求，超过30个连续的业务日。公司必须在2024年12月24日前，通过保持至少10个连续业务日的最低买盘价格1.00美元，以重新获得合规。如果Chimerix未能满足这一要求，且符合其他上市标准，则可能有资格获得额外的180天合规期，条件是转到纳斯达克资本市场。公司计划积极监测其股票价格，并考虑期权以重新获得合规。未能重新获得合规可能导致从纳斯达克退市。通知不会立即影响Chimerix在纳斯达克全球市场的上市或交易。公司将探索可用的其他选项来应对这一情况，但并不能保证重新获得合规或维持其他纳斯达克上市标准的成功。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    ImmunoPrecise Antibodies
    IPA
    -- 0.755
    Nutriband
    NTRB
    -- 7.280
    Metagenomi Technologies, LLC
    MGX
    -- 3.411
    Creative Medical Technology
    CELZ
    -- 2.8200
    Genelux
    GNLX
    -- 3.295
    解锁完整榜单
    热门中概股
    追踪最热门的中概股实时资讯。